The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions
The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio
Biocon Biologics is one among the three pharmaceutical companies from India to be featured on this year's list
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
Total transaction value of the divestment is Rs. 3,660 million
Punit has more than 20 years of experience in the generics and branded pharmaceutical marketplace
Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market
The companies will spread the adoption of the latest HOS and Mass Spec technologies to help scientists improve the safety, stability, and effectiveness of biotherapeutics
Amgen will be prohibited from leveraging its drug portfolio to disadvantage rivals and will be required to seek prior approval before acquiring related products
ABB India has secured an order from Reliance Life Sciences to deploy automation and control solutions for their new biosimilars and plasma proteins manufacturing facilities in Nashik, Maharashtra
Subscribe To Our Newsletter & Stay Updated
